Healthcare Global Enterprises Ltd Q3 FY2024 Concall Summary

Key Takeaways

• Seasonal softness, structural story intact: Revenue grew 11% YoY to INR470 crores despite a seasonally muted Q3, while mature centers adjusted for one-off disruptions grew 12%.
• Radiation mix is the margin engine: Four new radiation machines ramped in nine months, lifting radiation revenue 13% faster than overall revenue and improving the contribution margin even as topline dipped QoQ.
• Emerging centers are turning the corner: Kolkata halved its EBITDA loss QoQ, Nagpur grew 59% YoY, and Borivali is running at 20%-plus EBITDA margin, validating the cluster rollout model.
• 20% EBITDA margin guidance upheld, with a caveat: Management confirmed the target for the next two quarters, but flagged that the Indore acquisition and Whitefield project will pull margins down because Indore will not deliver 20% initially.
• What to watch next quarter: Whether the Chennai cyclotron restarts on schedule, the pace of Colaba's march to breakeven, and any concrete update on the Milann divestment timeline.

Mature vs Emerging Center Dynamics

• Mature center growth was optically soft: 8% YoY growth was depressed by the MSR shop-in-shop scale-down in Bangalore and Chennai flood disruption; adjusted growth was 12%.
• Occupancy fell on bed additions, not demand loss: Occupancy dropped from 65.7% to 58% because 45 beds were added in Baroda as capacity was reaching 70-75%, a pre-emptive move to meet future demand.
• Emerging centers are not capacity-constrained: Installed capacity has not been fully operationalized, so no emerging center faces a bed-count bottleneck.
• Kolkata and Mumbai turnaround is gaining traction: Investments in clinical talent and business promotion drove Kolkata to 57% growth and Mumbai to 17% growth, with Kolkata EBITDA losses halving QoQ from INR2.2 cr to INR1.1 cr.
• Nagpur and Ranchi delivered breakout growth: Nagpur grew 59% YoY and Ranchi 31% in Q3 FY24, showing the newer clusters are scaling.
• Borivali is the emerging-center benchmark: EBITDA margin is 20-plus percent, and the center ran out of LINAC capacity, prompting the addition of one more LINAC and robotics last quarter.
• Colaba is still loss-making but finding its footing: Positioned as a destination for international patients, it has seen tremendous success attracting them in the last 3-4 months and opened a women's wing focusing on breast and cervical cancer; management expects breakeven in a couple of quarters.

Ajai Kumar: "A center like Indore can come which is great for long-term opportunity, that can pull down your EBITDA for a while. So that is how we have to calculate this. Otherwise, we have to do only M&A activities, where all of them give us EBITDA margin of say 25%, then only we acquire it, then where is a growth, where is opportunity for growth for any investor?"

Margin Trajectory & Levers

• 20% EBITDA margin guidance is upheld: Management confirmed the target of achieving 20% EBITDA margin by Q4 or Q1 FY25, at least in the next two quarters.
• Two near-term margin headwinds are disclosed: The Indore acquisition (which will not deliver 20% EBITDA margin initially) and the Whitefield project becoming functional will pull down consolidated EBITDA margin to some extent.
• Radiation business is the structural margin driver: New machines installed across centers have already started showing results, with the radiation business picking up and helping contribution margin improve despite a QoQ revenue decline.
• ARPOB levers go beyond pricing: High-end treatments (robotics introduced in three more centers), faster turnaround, lower ALOS, and more linear accelerators driving radiation are the main levers, not just rate increases.
• Established centers already operate at 24% EBITDA margin: As emerging centers grow and mature, overall EBITDA margins should expand from this base.
• Chennai cyclotron disruption cost 30 bps of EBITDA: The cyclotron bunker flooded in November and the facility is still down; it is a highly profitable business and is expected to be up by end of this month.
• MSR scale-down was a strategic profitability drag: The decision to exit the last shop-in-shop model at M S Ramaiah Bengaluru affected profitability, but it clears the way for a new 100-bedded facility on airport road to capture North Bangalore and total Bangalore market share.

Ajai Kumar: "I don't know why you made a statement all hospitals at 25%. I don't think all hospitals are above 20%."

Capacity Expansion Pipeline

• 350 beds planned over three years: This includes the Ahmedabad relocation and the Whitefield project.
• Ahmedabad is relocating to a 200-bed premium facility: Moving from a 100-bed hospital to a newly constructed state-of-the-art facility in Q1 of the coming financial year; the existing hospital already runs at high-20s EBITDA margin and ~30% ROCE.
• North Bangalore gets a 100-bed comprehensive cancer center: A state-of-the-art advanced premium facility, similar to Ahmedabad, with an expected capital outlay of ~INR90 crores and operational in 15 to 18 months.
• Whitefield will add a 25-bed women's cancer center: A stand-alone comprehensive cancer center in East Bangalore focusing on women's cancer, ready early next year in FY26 or calendar year 2026.
• Indore Phase II capacity increase is planned but unformed: Management will share the plan when it is formed.
• No capacity constraints expected for the next 3 to 4 years: Pre-emptive actions are being taken for capacity requirements across the network.

Raj Gore: "It's a hospital, which has EBITDA margin in high 20s, ROCE around 30%." (on Ahmedabad)

Payer Mix & Affordability

• Cash plus TPA is the combined segment to watch: Management groups cash and TPA together and targets that combined segment as insurance penetration grows and cannibalizes pure out-of-pocket spend.
• Emerging centers in bigger cities carry a better payer mix: Higher affordability and insurance penetration in these cities mean the mix will improve as emerging centers contribute more to consolidated revenue.
• Public insurance margins vary by state: Odisha has better rates and timely payments; HCG's model can deliver 20-plus percent EBITDA margin even at government rates in Andhra (Vijayawada, Vizag) and Bhavnagar due to higher turnover and asset turn.
• ARPOB differential is driven by clinical complexity, not just pricing: HCG's ARPOB of INR42,800 (up 15% YoY) is higher than competitors because of technology mix, complicated recurrent cases, and destination-center status; mortality rate improvement from 3.4% to below 1% underscores quality of care.

Raj Gore: "I think the beauty of HCG model is... even at a government rate, we are able to deliver 20-plus margin, 20-plus percent EBITDA margin in Vijayawada, Vizag, similar case in Bhavnagar."

Strategic Initiatives & Digital

• HCG Care app launched as a lifetime patient-advisory platform: A first-of-its-kind app for cancer patients offering MDT consultations, second opinions, diagnostics, pharmacy, rehab, home care, and post-discharge follow-up, aimed at building long-term patient relationships.
• Indore acquisition integration is nearly complete: Acquired October 3, IT integration (HIS, ERP, CRM, websites) is done, and the facility upgrade (rooms, ICU, facade) is almost complete this month; Indore has been added to the North India cluster.
• Robotics expanded to three more centers: This supports the high-end treatment lever for ARPOB growth.
• Colaba women's wing opened: Specifically focusing on women's cancer, breast cancer, and cervical cancer, complementing the international patient destination strategy.

Raj Gore: "With this, we are confident of building a long-term relationship with our patients to be their structured adviser over a lifetime." (on the HCG Care app)

Guidance & Commitments

Key Metrics